PP
CLDX icon

PDT Partners’s Celldex Therapeutics CLDX Stock Holding History

PDT Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.1M Hold
97,822
– – 0.18% 183
2025
Q4 		$2.66M Hold
97,822
– – 0.17% 207
2025
Q3 		$2.53M Hold
97,822
– – 0.16% 221
2025
Q2 		$1.99M Buy
97,822
+76,923
+368% +$1.5M 0.11% 299
2025
Q1 		$379K Buy
+20,899
New +$467K 0.03% 569
2022
Q1 		– Sell
-16,327
Closed -$631K – 959
2021
Q4 		$631K Buy
+16,327
New +$712K 0.05% 472
2017
Q2 		– Sell
-21,247
Closed -$1.15M – 522
2017
Q1 		$1.15M Sell
21,247
-3,373
-14% -$176K 0.06% 302
2016
Q4 		$1.31M Sell
24,620
-3,933
-14% -$224K 0.09% 302
2016
Q3 		$1.73M Sell
28,553
-4,474
-14% -$279K 0.1% 243
2016
Q2 		$2.17M Buy
+33,027
New +$2.1M 0.17% 192

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.52B AUM 121.13% 1-Year Est. Return